BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22174670)

  • 1. Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry.
    Padmanabhan P; Dixit NM
    PLoS Comput Biol; 2011 Dec; 7(12):e1002307. PubMed ID: 22174670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection.
    Cowton VM; Angus AGN; Cole SJ; Markopoulou CK; Owsianka A; Dunlop JI; Gardner DE; Krey T; Patel AH
    J Virol; 2016 Aug; 90(16):7456-7468. PubMed ID: 27279607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural insights into hepatitis C virus receptor binding and entry.
    Kumar A; Hossain RA; Yost SA; Bu W; Wang Y; Dearborn AD; Grakoui A; Cohen JI; Marcotrigiano J
    Nature; 2021 Oct; 598(7881):521-525. PubMed ID: 34526719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.
    Lavie M; Sarrazin S; Montserret R; Descamps V; Baumert TF; Duverlie G; Séron K; Penin F; Dubuisson J
    J Virol; 2014 Sep; 88(18):10584-97. PubMed ID: 24990994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry.
    Qin ZL; Ju HP; Gao TT; Wang WB; Ren H; Zhao P; Qi ZT
    J Gen Virol; 2015 Jun; 96(Pt 6):1389-1399. PubMed ID: 25701820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential interaction strategies of hepatitis c virus genotypes during entry - An in silico investigation of envelope glycoprotein E2 - CD81 interaction.
    Bhattacharjee C; Nandy SK; Das P; Mukhopadhyay A
    Infect Genet Evol; 2019 Apr; 69():48-60. PubMed ID: 30639544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD81 Receptor Regions outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into Hepatoma Cells.
    Banse P; Moeller R; Bruening J; Lasswitz L; Kahl S; Khan AG; Marcotrigiano J; Pietschmann T; Gerold G
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29677132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus induces CD81 and claudin-1 endocytosis.
    Farquhar MJ; Hu K; Harris HJ; Davis C; Brimacombe CL; Fletcher SJ; Baumert TF; Rappoport JZ; Balfe P; McKeating JA
    J Virol; 2012 Apr; 86(8):4305-16. PubMed ID: 22318146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry.
    McCaffrey K; Boo I; Owczarek CM; Hardy MP; Perugini MA; Fabri L; Scotney P; Poumbourios P; Drummer HE
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor.
    Wünschmann S; Medh JD; Klinzmann D; Schmidt WN; Stapleton JT
    J Virol; 2000 Nov; 74(21):10055-62. PubMed ID: 11024134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81.
    Rajesh S; Sridhar P; Tews BA; Fénéant L; Cocquerel L; Ward DG; Berditchevski F; Overduin M
    J Virol; 2012 Sep; 86(18):9606-16. PubMed ID: 22740401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.
    Ashfaq UA; Qasim M; Yousaf MZ; Awan MT; Jahan S
    J Transl Med; 2011 Nov; 9():194. PubMed ID: 22074322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.
    Rothwangl KB; Manicassamy B; Uprichard SL; Rong L
    Virol J; 2008 Mar; 5():46. PubMed ID: 18355410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a novel drug lead that inhibits HCV infection and cell-to-cell transmission by targeting the HCV E2 glycoprotein.
    Al Olaby RR; Cocquerel L; Zemla A; Saas L; Dubuisson J; Vielmetter J; Marcotrigiano J; Khan AG; Vences Catalan F; Perryman AL; Freundlich JS; Forli S; Levy S; Balhorn R; Azzazy HM
    PLoS One; 2014; 9(10):e111333. PubMed ID: 25357246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-function analysis of hepatitis C virus envelope-CD81 binding.
    Petracca R; Falugi F; Galli G; Norais N; Rosa D; Campagnoli S; Burgio V; Di Stasio E; Giardina B; Houghton M; Abrignani S; Grandi G
    J Virol; 2000 May; 74(10):4824-30. PubMed ID: 10775621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.
    Bitzegeio J; Bankwitz D; Hueging K; Haid S; Brohm C; Zeisel MB; Herrmann E; Iken M; Ott M; Baumert TF; Pietschmann T
    PLoS Pathog; 2010 Jul; 6(7):e1000978. PubMed ID: 20617177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into Hepatitis C Virus E2
    Risueño C; Abrescia NGA; Coluzza I
    J Phys Chem B; 2022 Oct; 126(42):8391-8403. PubMed ID: 36255318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins.
    Kalemera MD; Capella-Pujol J; Chumbe A; Underwood A; Bull RA; Schinkel J; Sliepen K; Grove J
    J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33147126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.
    Harman C; Zhong L; Ma L; Liu P; Deng L; Zhao Z; Yan H; Struble E; Virata-Theimer ML; Zhang P
    J Virol; 2015 Jan; 89(1):492-501. PubMed ID: 25339761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection.
    Meola A; Sbardellati A; Bruni Ercole B; Cerretani M; Pezzanera M; Ceccacci A; Vitelli A; Levy S; Nicosia A; Traboni C; McKeating J; Scarselli E
    J Virol; 2000 Jul; 74(13):5933-8. PubMed ID: 10846074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.